GlassScriptPhysician profile
Spencer Ng
NPI 1235633652
$6,661.51
in general payments reported to CMS, 2019-2025
14 companies · $3,963 in 2025
The $3,963 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $882 · 2020: $327 · 2021: $745 · 2022: $661 · 2023: $82.96 · 2025: $3,963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,455 · Food and Beverage: $565 · Travel and Lodging: $25.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,455.00 |
| Food and Beverage | $565.48 |
| Travel and Lodging | $25.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $3,866.10 | 2019-2025 | |
| Abbvie INC. | $1,382.55 | 2019-2022 | |
| Galderma Laboratories, L.P. | $265.52 | 2022 | |
| Lilly USA, LLC | $256.52 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $156.01 | 2019-2022 | |
| Janssen Biotech, INC. | $130.69 | 2021-2025 | Carvykti, Rybrevant |
| Janssen Scientific Affairs, LLC | $124.24 | 2025 | Tremfya |
| Kyowa Kirin, INC. | $119.14 | 2019 | |
| Pfizer INC. | $96.67 | 2020 | |
| Regeneron Pharmaceuticals, INC. | $85.97 | 2025 | Dupixent |
| Abbott Laboratories | $82.96 | 2023 | Mitraclip |
| Ucb, INC. | $41.25 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.22 | 2025 | Lifevest |
| Amgen INC. | $20.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spencer Ng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.